Form 8-K - Current report:
SEC Accession No. 0001437749-25-038605
Filing Date
2025-12-23
Accepted
2025-12-23 08:46:03
Documents
13
Period of Report
2025-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sava20251222_8k.htm   iXBRL 8-K 27679
  Complete submission text file 0001437749-25-038605.txt   158530

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sava-20251219.xsd EX-101.SCH 3580
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20251219_def.xml EX-101.DEF 11425
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20251219_lab.xml EX-101.LAB 15311
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20251219_pre.xml EX-101.PRE 11585
15 EXTRACTED XBRL INSTANCE DOCUMENT sava20251222_8k_htm.xml XML 2868
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 251595042
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)